Does Oral Methamphetamine Speed Reactions More in Women Than Men? What 73 Volunteers Actually Showed

Short answer: In a controlled, double-blind, four-session experiment involving 73 healthy adults, a single 20-mg oral methamphetamine dose was associated with faster button-press reaction times in women but no statistically detectable reaction-time change in men. The estimated drug-by-gender interaction was significant (p = 0.009). The result concerned a brief computer-based monetary-cue task, not driving performance, a toxicology concentration threshold, or a test that diagnoses impairment in an individual. No methamphetamine concentration in blood, plasma, serum, or oral fluid was established by this experiment.

The primary source is Mayo, Paul, DeArcangelis, Van Hedger, and de Wit (2019), “Gender differences in the behavioral and subjective effects of methamphetamine in healthy humans,” Psychopharmacology 236:2413–2423, doi:10.1007/s00213-019-05276-2. The authors tested whether methamphetamine interacted with anticipated monetary gain or loss differently in participants categorized as men and women. Their key observation was a difference in overall reaction-time response to the drug, not a drug-specific enhancement of responding to rewarding cues.

What exactly did the investigators find?

The investigators analyzed complete monetary-incentive task data from 44 men and 29 women. Every participant attended two active-drug sessions and two placebo sessions, so the experiment had 73 independent behavioral participants rather than 292 independent people. During the task, estimated marginal mean response time in women was 287.4 milliseconds on placebo and 272.7 milliseconds on methamphetamine: a 14.7-millisecond decrease. In men the corresponding estimates were 263.3 and 261.4 milliseconds, a 1.9-millisecond decrease. The authors’ mixed-effects model identified a drug-by-gender interaction of approximately −12.82 milliseconds, with p = 0.009.

A smaller reaction time means the participant pressed the target button sooner. It does not necessarily mean that the participant made a safer decision, drove better, exercised better judgment, or had a lower probability of error in an unfamiliar real-world task. Participants completed a controlled visual reaction-time procedure with predictable monetary contingencies. The article’s precision depends on keeping that measured behavioral endpoint separate from legal and clinical concepts of intoxication or impairment.

How was the placebo-controlled study structured?

The volunteers were healthy adults aged 18–35, screened for medical and psychiatric exclusions. The group included 44 men and 29 women, with a mean overall age of approximately 24.8 years. They attended four laboratory visits lasting about four hours each, separated by at least 48 hours. Treatment alternated in counterbalanced sequences: methamphetamine, placebo, methamphetamine, placebo, or the inverse sequence. Participants and researchers were blinded to the active treatment. Each active visit involved a fixed, non-weight-adjusted oral dose of 20 mg methamphetamine administered in syrup; placebo consisted of matching syrup.

The two active-drug visits and two placebo visits were averaged within treatment because the investigators did not observe relevant differences between repeated sessions of the same condition. Thus, the reported drug contrast compares within-participant mean performance across controlled sessions. The dose, route, volunteer selection, timing, and repeated design matter. This was neither a naturalistic study of people using smoked or injected methamphetamine nor a survey of motorists stopped by police. A fixed oral dose in screened young volunteers is an experimental exposure, not a general-purpose pharmacological model of every illicit or therapeutic exposure.

When and how was reaction time measured?

Participants performed the monetary incentive delay task roughly 30–70 minutes after administration. Each trial displayed a cue, followed by a short anticipation period and a visual target. The target remained available for 0.5 second; participants were asked to press a button as quickly as possible. There were 40 trials per task administration. Cues signaled the chance to win money, avoid losing money, or receive no monetary consequence. Potential monetary stakes were $0.25 or $1.00. The researchers recorded reaction time and whether a response occurred within the task’s permitted window.

The task used a fixed presentation interval rather than individually adjusting difficulty to generate more failures. As a result, the reported success rate was about 98%. That ceiling reduces the usefulness of hit-rate changes for identifying whether the stimulant enhanced accurate performance. A participant can become faster without establishing a meaningful improvement in a high-stakes task requiring divided attention, hazard detection, memory, and accurate decisions. The specific task environment is especially important before applying the study to a driving or workplace dispute.

Original evidence table: reaction times by gender and treatment

The confidence intervals refer to separate estimated marginal means; they are not confidence intervals around the within-person change or around the interaction. The statistically significant interaction derives from the study’s mixed-effects model rather than a visual comparison of whether those separate confidence intervals overlap. Men were faster than women at the placebo session on average, and a potential baseline performance ceiling was acknowledged by the authors. The study does not show that women were absolutely faster than men after taking the drug.

Did methamphetamine specifically amplify the effect of financial rewards?

No specific reward-cue potentiation was demonstrated. In both treatment conditions participants generally pressed faster when larger incentives were possible, whether the goal was to gain money or avoid a loss. That cue effect should not be mistaken for methamphetamine selectively magnifying anticipation of a win or a loss. The authors removed nonsignificant interactions involving trial type from their final mixed-effects model, which reflected an effect of the drug on women’s responses across the different cue categories rather than a unique interaction with the reward value of the cues.

This null distinction is fundamental to the experiment’s original question. A simplistic account that “methamphetamine made women more reward-seeking” goes beyond the measured outcome. Reaction time to a visual cue is not a direct measurement of dopamine release, risk preference, willingness to gamble in actual life, or later development of addiction. The researchers discussed potential dopamine-related mechanisms, but this experiment did not directly assay dopamine or image reward circuits during task performance. It measured keypress latency in a structured monetary task.

Original evidence table: significant and nonsignificant model effects

The study’s model coefficients depend on the selected reference categories and the interaction structure. The reference-category drug coefficient of −1.98 ms with p = 0.515 is not a universal estimate of stimulant effects in all populations. Equally, the significant interaction does not establish that every woman would have a faster response or that every man would not. Repeated within-subject measures, between-person variability, and the chosen statistical model are all part of the inference.

How did self-reported stimulant effects differ?

Both participant groups reported the expected acute stimulant profile on methamphetamine compared with placebo. Across the 73-person sample, the drug increased ratings of feeling the drug, liking its effects, feeling high, and wanting more. The Profile of Mood States also showed an overall increase in vigor and reductions in fatigue. These ratings are subjective outcomes collected at specified times, not chemical assays and not independently verified indicators of task accuracy.

Two reported interactions were particularly relevant to gender. Women had a greater increase in the POMS vigor scale (p = 0.009 for the drug-by-gender interaction) and a larger reduction in the ARCI PCAG sedative-like score (p = 0.011). The source Table 2 gives women’s vigor peak-change score as −2.90 in the placebo condition and +4.10 under methamphetamine; men’s respective values were −1.43 and +1.77. For ARCI PCAG, women shifted from +3.28 to −0.57, compared with men shifting from +1.84 to +0.25. Those values represent changes in scale scores, not blood drug concentrations or milliseconds.

Which self-reported effects were not independently different between genders?

It would be inaccurate to infer that every subjective response was more intense in women. The paper found no gender effect on any Drug Effects Questionnaire scale, even though methamphetamine changed many of those ratings overall. Increased “like effects,” “feel high,” and “want more” scores were drug effects, not demonstrated gender-specific increases. The apparent trend toward a greater increase in friendliness in women did not survive the investigators’ multiple-comparison procedure, despite a nominal p = 0.041.

The authors also noted that some positive mood outcomes observed in a larger sample of 90 participants did not reach statistical significance in the 73-person behavioral subgroup. It is important not to assign the larger 90-person denominator to the monetary-cue reaction-time experiment or claim that the larger supplementary dataset validates every subgroup effect. The main response-time sample contained 73 people; the 90-person collection contributed additional mood and cardiovascular analyses and is not a second independent replication.

What happened to heart rate and blood pressure?

Oral methamphetamine increased group heart rate and mean arterial blood pressure, consistent with acute stimulant physiological effects. The investigators reported a heart-rate drug effect with F(1,72) = 56.4, p < 0.001, and a mean-arterial-pressure drug effect with F(1,71) = 140, p < 0.001. For blood pressure, the paper also reported an overall gender term, but importantly the drug-by-gender interaction was not significant (p = 0.82). The investigators likewise did not find a gender interaction for heart rate.

This pattern cautions against a simple theory that a greater female reaction-time effect must result from a greater cardiovascular response to the same dose. It does not resolve the biological mechanism: no measured individual exposure curves or metabolic genotypes were provided to explain the behavioral differences. A larger or smaller pulse increase cannot be used as a replacement measure for reaction time, concentration, or impairment in a case. Cardiovascular and behavioral outcomes must be interpreted separately.

Were actual methamphetamine blood or plasma concentrations measured?

Not for the drug-response comparisons reported here. Investigators gave a known oral 20-mg administered dose and monitored behavioral, self-report, and cardiovascular outcomes. Before each visit they used breath-alcohol screening, urine drug screening, and pregnancy testing where applicable to check eligibility and adherence to study restrictions. Those preliminary screenings are not a series of quantitative methamphetamine assays in forensic whole blood, plasma, serum, or oral fluid.

Because the primary paper supplied no measured methamphetamine concentration-time series, it cannot yield a dose-to-blood calibration curve, sex-specific blood concentration adjustment, pharmacokinetic area under the curve, elimination half-life, or an impairment threshold. The nominal 20-mg dose should not be rewritten as a blood level. Differences in route, formulation, ingestion timing, coexposures, and metabolism can affect actual circulating concentrations, but their magnitude was not established through a measured methamphetamine concentration series in this experiment.

What do “gender differences” mean in this particular paper?

The original investigators categorized participants as men and women and used the term “gender” for the between-person grouping variable. The experimental dataset does not support replacing that research coding with an individualized conclusion about chromosomes, hormones, gender identity, or sex-specific metabolism. Women who were not taking hormonal contraception had their laboratory sessions scheduled during the follicular phase. This design choice restricts generalization to other menstrual-cycle phases, and the researchers themselves recognized that limitation.

Men and women also differed in placebo reaction times, body weight distributions, and some demographic characteristics. Body weight and body mass index were examined and did not explain the principal interaction in the model as reported. Nevertheless, a fixed 20-mg dose gave different milligrams-per-kilogram exposures across participants, and the study did not measure CYP2D6 genotype or actual drug concentrations. A group-level interaction should never be converted into a clinical rule that one gender is necessarily “more impaired” than another at a hypothetical blood result.

Why does baseline performance matter when interpreting stimulant effects?

Men’s placebo task responses were already faster than women’s on average. Their estimated placebo latency was 263.3 ms, compared with 287.4 ms for women. After methamphetamine, the estimates moved to 261.4 and 272.7 ms. One possibility raised by the authors is that the faster placebo baseline made an additional medication-related speed gain harder to detect in the men. They also observed that men could speed up under high-incentive cues, indicating that a complete physical response-time floor had not been demonstrated.

In a forensic assessment, this distinction matters because a change from the person’s own baseline is different from ranking two people against one another. The repeated-condition design estimated average within-participant drug effects, whereas a roadside encounter rarely includes the same person’s placebo task under matched circumstances. Without that baseline, a rapid or slow response by itself cannot identify which drug was present, whether a dose was recent, whether a concentration is expected, or whether the observed behavior was caused by methamphetamine.

Does a faster laboratory response demonstrate safer driving?

No. The experiment had no on-road or simulator driving endpoint. A monetary-cue target appearing on a computer screen does not reproduce steering, lane position, vehicle following, divided attention, hazard anticipation, fatigue, braking decisions, or compliance with traffic rules. A faster target-button press could coexist with altered judgment or other cognitive performance not tested in the protocol. The data cannot quantify a person’s likelihood of being a safe or unsafe driver or demonstrate a causal role in any particular crash.

Neither the significant sex-by-drug interaction nor the nonsignificant overall reference-category drug coefficient is a validated driving-impairment test. It would be unsound to extrapolate from a roughly 15-ms reduction in women’s model-estimated latency to a predicted reduction in stopping distance in traffic. Braking requires stimulus recognition, selection of an appropriate action, vehicle dynamics, and response to a real hazard; the paper directly measured none of those. The study remains useful as evidence that behavioral drug effects can vary with baseline performance and the particular task administered.

Can this experiment establish a forensic methamphetamine concentration cutoff?

No concentration cutoff can be derived because the investigators did not report quantitative methamphetamine analysis of blood, plasma, serum, or oral fluid. In a case involving a chemical test, the first questions concern which biological matrix was sampled, what analyte was measured, the analytical method, and the time of collection. A drug administered orally in a blinded laboratory visit should not be equated with a measured forensic specimen from another person’s encounter.

When a real blood or other specimen result is at issue, analytical identity and quantitation require appropriate confirmatory testing and validation for the particular matrix. A medication history, exact collection time, route of administration, active enantiomer and possible coexposures may all be relevant. Even a valid confirmed result is not transformed by this 73-person task experiment into a universal individual motor-performance prediction. Additional clinical, behavioral and event-specific evidence would be necessary for an impairment or causation opinion.

What limits the reliability and external validity of the findings?

The sample comprised healthy adults aged 18–35 under medically screened, structured conditions. It excluded many health, psychiatric, medication and sleep-related circumstances that occur in forensic practice. Only one methamphetamine dose, one oral formulation and one broad reaction-time paradigm were tested. Repeated sessions helped control individual differences but did not create evidence about chronic exposure, tolerance, high-dose intoxication, withdrawal, sleep deprivation, polydrug exposure, or emergency decision-making. The reaction-time task itself produced a very high success rate, limiting sensitivity to errors.

Gender was measured as a two-level study grouping; no comprehensive hormone exposure analysis or measured plasma methamphetamine kinetics established why the interaction arose. The absence of a drug effect in the men’s subgroup is not proof that every man is unaffected. The positive interaction is not proof that all women show improved function. Post hoc subjective comparisons underwent Benjamini–Hochberg correction, and a nominal friendliness contrast did not remain significant. These methodological limits are central to an accurate statement of what this one original study contributes.

How should the findings be used in a forensic toxicology review?

The appropriate limited conclusion is that a controlled oral dose altered group-level visual reaction-time performance differently in men and women, while reward-magnitude cues had their own effects and a distinct reward-specific drug interaction was not established. A forensic analysis should describe the task, baseline, actual dose, sample composition, effect size, statistical comparisons, and the outcomes not measured. It should avoid treating experimental mean latency as a direct proxy for impairment or as a calibration factor for a blood concentration obtained in an unrelated matter.

When laboratory toxicology evidence exists independently, consider the true specimen and assay, time from alleged event to collection, documented drug and medication history, collection and storage circumstances, and any clinically or behaviorally observed functions. The principles for reviewing timing and sampling in therapeutic drug monitoring can help frame those questions, but therapeutic concentration ranges are not automatically legal impairment boundaries. A narrow experimental result should remain a narrow experimental result, however important it may be to understanding human variability.

Frequently asked questions

1. How many people were studied, and why not 292?

Seventy-three adults had complete task data: 44 men and 29 women. Each attended four sessions, two with active methamphetamine and two with placebo. Those repeat visits are observations on the same people, not 292 independent individuals. Additional mood and cardiovascular data for 90 people did not enlarge the 73-person primary behavioral cohort.

2. Was methamphetamine given intravenously, smoked, or orally?

It was administered orally as a fixed 20-mg dose in a matching syrup preparation. The experiment does not quantify responses to smoked, injected, or higher doses. It also does not provide a direct blood concentration curve for this dose.

3. Did women actually become faster than men after the drug?

No such reversal was shown. Women’s mean modeled reaction time decreased by 14.7 ms under drug compared with placebo, whereas men’s decreased by 1.9 ms. Men’s responses remained faster in absolute group means under both conditions. The reported p = 0.009 describes an interaction in the change between groups.

4. Did the monetary reward cues become more powerful specifically because of methamphetamine?

No significant drug-specific reward-magnitude interaction was established. High potential gain and high potential loss each elicited faster responses than no incentive, but the gender-linked methamphetamine change was observed across cue categories. Response speed is not equivalent to real-world reward-seeking or future addiction.

5. Were there significant effects that were not gender-specific?

Yes. Overall methamphetamine increased many self-rated stimulant experiences, heart rate, and blood pressure. The investigators reported no significant drug-by-gender interactions for heart rate or mean arterial blood pressure, and no gender effect on any Drug Effects Questionnaire scale. Not every subjective or physiological effect followed the reaction-time pattern.

6. Could the findings validate a methamphetamine blood-level impairment threshold?

No. This original experiment did not provide quantified methamphetamine concentrations in blood, plasma, serum or oral fluid or measure standardized actual driving impairment. A nominal oral dose and a group reaction-time comparison cannot define a concentration cutoff for a different person’s alleged incident.

7. Can a 14.7-millisecond task effect prove causation in a crash or workplace event?

No. The study measured button-press latency during a controlled monetary-cue task, not the event, the person’s whole-blood concentration, actual hazards, complex decisions or competing explanations. Any individualized opinion would require additional case-specific evidence and cannot be derived from this mean group response alone.

Primary study and scope of interpretation

Original primary research: Mayo LM, Paul E, DeArcangelis J, Van Hedger K, de Wit H. “Gender differences in the behavioral and subjective effects of methamphetamine in healthy humans.” Psychopharmacology. 2019;236:2413–2423. https://doi.org/10.1007/s00213-019-05276-2. This analysis independently restates selected original results and separates observed laboratory outcomes from scientific questions not evaluated in the trial. The original work was published under a Creative Commons Attribution 4.0 license; no source figures or full original tables are reproduced here. The evidence is educational and cannot substitute for examination of a complete forensic case record.